KA
IBRX icon

Kercheville Advisors’s ImmunityBio IBRX Stock Holding History

Kercheville Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.64M Buy
644,685
+1,548
+0.2% +$11.7K 1.72% 21
2026
Q1 		$4.93M Buy
643,137
+58,963
+10% +$404K 1.58% 20
2025
Q4 		$4.29M Buy
584,174
+65,074
+13% +$147K 1.12% 28
2025
Q3 		$1.28M Buy
519,100
+418,600
+417% +$1.08M 0.39% 49
2025
Q2 		$265K Buy
+100,500
New +$270K 0.09% 82

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kercheville Advisors's IBRX Position: Q2 2026 in Review

Kercheville Advisors increased its ImmunityBio (IBRX) stake by 0.24% in Q2 2026, buying an estimated $11.7K and bringing the position to 644,685 shares worth $5.64M. The position accounts for 1.72% of the portfolio, ranked #21.

Kercheville Advisors first reported a position in IBRX in Q2 2025 and has held it in 5 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Kercheville Advisors held 644,685 shares of ImmunityBio worth $5.64M as of Q2 2026.
  • Kercheville Advisors bought 1,548 ImmunityBio shares in Q2 2026, an estimated $11.7K.
  • ImmunityBio made up 1.72% of Kercheville Advisors's portfolio in Q2 2026, its #21 holding.
  • Kercheville Advisors first reported a position in ImmunityBio in Q2 2025 and has held it in 5 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Kercheville Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.